Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer

Inclusion Criteria: * Advanced NSCLC that cannot undergo curative surgery. * Patients that are refractory to standard chemotherapy or cannot be treated with further therapy due to severe adverse effects of chemotherapy. * Histologically diagnosed NSCLC. * Clinical efficacy can be evaluated by radiologic methods within 4 weeks prior to receiving treatment. * ECOG performance status 0-2 within 2 weeks prior to receiving treatment. * Life expectancy \> 3 months. * Age between 20 to 79 * Male or Female. * In patients or out patients. * Able and willing to give valid written informed consent. Exclusion Criteria: * Other malignancy requiring treatment * radiation, immunotherapy, hyperthermia, or surgery. * Active and uncontrolled infectious disease * Active and uncontrolled hepatic dysfunction, kidney dysfunction, cardiac disease, or lung disease (i.e. interstitial pneumonia). * Autoimmune disease. * HIV-Ab or antigen positive * Prior anti-cancer therapy within 4 weeks * Laboratory values as follows: 2000\<mm3 \< WBC \< 15000/mm3, Platelet count \< 50000/mm3, Asparate transaminase \> 5 X cutoff value, Alanine transaminase \> 5 X cutoff value, Total bilirubin \> 3 X cutoff value, and Serum creatinine \> 3X cutoff value. * Patients knows HLA-A type. * Breastfeeding and Pregnancy (woman of child bearing potential) * Refusal of pregnancy conception. * Treated with S-488401, S-488402, or S-488403. * Treated with other investigational drug within 3 months prior to receiving S-48810 treatment. * Decision of nonenrollment of the patients by principal investigator or physician-in-charge from the view point of patient's safety.